biostudies-literatureWu XScience and Technology planning project of Guizhou ProvinceScience and Technology Foundation of Health Commission of Guizhou ProvienceScience and Technology Planning Project of Guiyang, Guizhou Provience, Chinaresearch project in the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine14632https://www.ebi.ac.uk/biostudies/studies/S-EPMC9420103biostudies-literatureUnknown12(1)As one of the most common malignancies, gastric cancer (GC) is the third leading cause of cancer-related deaths in China. GC is asymptomatic in early stages, and the majority of GC mortality is due to delayed symptoms. It is an urgent task to find reliable biomarkers for the identification of GC in order to improve outcomes. A combination of dried blood spot sampling and direct infusion mass spectrometry (MS) technology was used to measure blood metabolic profiles for 166 patients with GC and 183 healthy individuals, and 93 metabolites including amino acids, carnitine/acylcarnitines and their derivatives, and related ratios were quantified. Multiple algorithms were used to characterize the changes of metabolic profiles in patients with GC compared to healthy individuals. A biomarker panel Scientific reportsMetabolite biomarker discovery for human gastric cancer using dried blood spot mass spectrometry metabolomic approach.PMC9420103ZK[2022] General 494GZEYK[2020]6gzwjkj2020-1-185[2019]-9-4-28Zhu ZAo HGao HWu XfalseMetabolite biomarker discovery for human gastric cancer using dried blood spot mass spectrometry metabolomic approach.As one of the most common malignancies, gastric cancer (GC) is the third leading cause of cancer-related deaths in China. GC is asymptomatic in early stages, and the majority of GC mortality is due to delayed symptoms. It is an urgent task to find reliable biomarkers for the identification of GC in order to improve outcomes. A combination of dried blood spot sampling and direct infusion mass spectrometry (MS) technology was used to measure blood metabolic profiles for 166 patients with GC and 183 healthy individuals, and 93 metabolites including amino acids, carnitine/acylcarnitines and their derivatives, and related ratios were quantified. Multiple algorithms were used to characterize the changes of metabolic profiles in patients with GC compared to healthy individuals. A biomarker panel 2022-01-01T00:00:00Z2022 Aug2025-04-04T13:46:40.677Z2025-04-04T13:46:40.677ZS-EPMC94201033603030010.1038/s41598-022-19061-3